30 minutes, no charge. A short conversation to understand your program, current question, timeline, and whether Polaris is the right fit.

Hourly or fixed-scope support for defined questions such as an assay concept, CRO proposal/SOW, study plan, early cyno design, or data interpretation issue.

A fixed-scope deliverable such as an assay roadmap, decision-gated study plan, CRO proposal review, or preclinical risk assessment.

Monthly or project-based support for active programs requiring continued biology input, CRO-interface support, troubleshooting, and next-step decision guidance.

Polaris helps lean biotech teams translate therapeutic biology and mechanism-of-action hypotheses into executable study plans, CRO-ready scopes, and decision-ready data packages.

This includes clarifying the biological question, sequencing assays and studies, pressure-testing CRO proposals or SOWs, supporting execution when studies are outsourced, and helping founders interpret data in the context of program decisions.

Many assays may be scientifically reasonable in isolation. Polaris helps founders decide which studies are most relevant now — given the program stage, available data, timeline, budget, and next value inflection point.

Polaris is most useful when a program is moving from scientific concept into study planning, CRO engagement, or data-driven decision making.

This may be before signing a CRO SOW, launching a functional assay campaign, selecting an in vivo model, building an investor- or board-facing data package, or deciding what to do after early data come back. Polaris can also help when a team has strong biology but limited internal translational biology bandwidth, or when multiple technically reasonable study options need to be prioritized under timeline and budget constraints.

The earlier Polaris is brought in, the easier it is to shape a focused evidence path before scope, cost, and execution assumptions become locked in.

A CSO may define the scientific direction. A KOL may provide expert advice. A CRO may execute the work. Polaris focuses on the layer that often sits between them: translating biology into executable study plans and keeping outsourced work connected to the program decision it is meant to support.

For lean biotech teams, this layer can be critical. Expert advice can become fragmented if it is not converted into a practical workflow. CRO execution can drift if the biological question, assay logic, and decision criteria are not clearly carried through the process. Polaris helps founders bridge those gaps through study planning, CRO-interface support, troubleshooting, and data interpretation.

Polaris does not replace internal leadership, external experts, or CROs. It helps integrate them into a clearer decision flow.

Yes. Polaris can review CRO proposals, assay plans, study scopes, timelines, and key assumptions before a SOW is finalized.

This can help founders identify whether the proposed work is aligned with the biological question, whether the assay or model is appropriate for the program stage, and whether the scope is likely to generate decision-useful data.

The goal is not simply to negotiate cost. It is to make sure the planned work is scientifically coherent, feasible, and tied to the next program-critical decision before budget and timelines are committed.

Yes. Polaris can join CRO-facing study planning, execution check-in, troubleshooting, and data review meetings as founder-side scientific support.

In these meetings, Polaris helps keep the discussion connected to the biological question, assay logic, study assumptions, and decision criteria. This may include preparing questions in advance, clarifying CRO recommendations, identifying gaps or risks, and helping translate meeting outcomes into practical next steps.

The role is collaborative, not adversarial. The goal is to help founders get clearer scientific value from CRO execution and make sure important assumptions do not get lost between the proposal, the experiment, and the decision.

Polaris is a good fit for early therapeutic programs where biology, assay strategy, CRO execution, and development decisions are closely linked.

This may include antibody, bispecific, ADC, T-cell engager, immunology, oncology, or other mechanism-driven programs where the team needs to translate biology into functional assays, in vivo studies, CRO scopes, or decision-ready data packages.

Polaris is especially useful when the next study choice has real consequences for timeline, budget, investor milestones, or program direction.

Yes. Polaris is based in the San Francisco Bay Area and may be able to support in-person working sessions, founder discussions, or CRO-facing meetings depending on location, scope, and scheduling.

Polaris can also support scientific discussions in both English and Mandarin. This may be helpful for teams working with China-based CROs, cross-border collaborators, or bilingual scientific stakeholders where technical nuance, study assumptions, and decision context need to be communicated clearly.

The goal is to make complex translational biology and CRO execution discussions easier to align across teams, not just easier to translate word-for-word.